Pfizer completes Baxter vaccine acquisition

Drugmaker Pfizer Inc. said Monday it completed the acquisition of Baxter International Inc.'s portfolio of marketed vaccines.

Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where some vaccines are manufactured. The two vaccines are called NeisVac-C and FSME-IMMUN/TicoVac.

NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococci (MenC).

FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis, an infection of the brain, which is transmitted by the bite of ticks infected with the TBE-virus.

New York-based Pfizer's facility in Collegeville handles some of the company's vaccine research. - David Sell